會員登入
註冊
BNCT in Taiwan! Heron Neutron surges on IPO debut
2025-09-17 / GlobalBio & Investment
HeronNeutronMedicalCorp(7799.TW)madeastellardebutthisweek,listingatNT$600andsoaringnearly29%,overtakingBoraPharmaceuticals(6472.TW)asTaiwan'snewbiotechIPOleader.Foundedin2017,HeronNeutronpioneersA...
Synmosa Biopharma Moves to Acquire up to 30% of Genovate Bio at a 30% Premium
2025-09-16 / 新聞中心
SynmosaBiopharma (4114.TWO)announcedthatitsBoardhasapprovedaplantoacquire15%–30%ofGenovateBio (4130.TWO)sharesthroughapublictenderofferatNT$24pershare—a30%premiumoverGenovate'slatestcl...
Shine-On Bio Licenses Exosome Drug Tech to ESCO Aster for NT$200M
2025-09-16 / GlobalBio & Investment
Shine-OnBio(StockCode:6926.TWO)hassignedalicensingagreementworthoverNT$200MwithSingapore’sleadingbiopharmacompanyESCOAster(EA),grantingrightstoitspatentedexosome-basedsmallmoleculedrug-loadingte...
Sartorius AI Screening Platform Partners with Mycenax CDMO to Capture Global Biologics Market
2025-08-21 / GlobalBio & Investment
MycenaxBiotech,Inc.(4726.TWO)recentlyannouncedastrategic cooperationwithSartoriustoenhanceCDMOcapacityinAsia.Mycenaxhasintroducedthecutting-edge4Cell®CHOcelllinedevelopmentplatformdevelopedbySarto...
Biotech Is Heating Up—But Exosomes Are on Fire!
2025-08-07 / GlobalBio & Investment
WithBIOAsia–Taiwanjustaroundthecorner,biotechisbuzzing—butonekeywordisstealingthespotlightlikeneverbefore:Exosomes.Onceanichetopic,exosomesandextracellularvesicles(EVs)haveburstintomainstr...
BIO Asia–Taiwan 2025 Wraps with Record-Breaking Momentum—Taiwan Reclaims Its Role as Asia’s Biotech
2025-07-28 / GlobalBio & Investment
BIOAsia–Taiwan2025WrapswithRecord-BreakingMomentum—TaiwanReclaimsItsRoleasAsia’sBiotechHub!Overfour-daygathering,BIOAsia–Taiwan2025broughttogether: 850exhibitorsacross2,200boot...
NBRP Showcases Taiwan’s Biotech Powerhouse at BIO Asia–Taiwan!
2025-07-27 / GlobalBio & Investment
TheNationalBiotechnologyResearchPark(NBRP)debutsunderthetheme“RootedinMountains,ClimbingthePeaks,”symbolizingTaiwan’sscientificresilienceanditsambitiontoscalenewheightsinbiomedicalin...
FDA Modernization Act 3.0 is here—Can iPSC lead the future of animal-free drug testing?
2025-07-27 / GlobalBio & Investment
AtBIOAsia–Taiwan2025,LumiSTARBiotechnologyandMolecularDevices(HK)hostedacutting-edgeSatelliteSymposiumonNext-GenerationApproachesinDrugDevelopment,spotlightingiPSC-deriveddiseasemodels,high-thro...
PRIM Protein, Next-Gen ADCs & Brain-Targeting Nano Platform—3 Highlights You Can’t Miss
2025-07-27 / GlobalBio & Investment
AtBIOAsia–Taiwan’sDay2InnovationForumA-6,expertsfromABBiosciences,OBIPharma,andNanocarryTherapeuticsunveiledcutting-edgeantibodyinnovations:Dr.Yen-MingHsu,FounderofABBiosciences,introduced...
Taiwan Bio Therapeutics & Mayo Clinic Launch Phoenix Investment Plan
2025-07-27 / GlobalBio & Investment
Focus:CellManufacturing&RegulatoryTCellTherapiesDuringBIOAsia–Taiwan2025,TaiwanBioTherapeutics(6892.TWO)announcedthesigningofanewtermsheetwithMayoClinic,deepeningtheirpartnershipandofficiall...
The Future of CGT: Gene Editing, Hypoimmune Platforms & Decentralized Manufacturing
2025-07-27 / GlobalBio & Investment
Atthe2025BIOAsia–TaiwanInnovationForumSA-2,leadingU.S.-basedexpertsinadvancedgeneandcelltherapygatheredtosharecutting-edgetechnologiesandcommercializationstrategiesthatareredefiningthefutureofCG...
Exploring the Next Generation of Therapies
2025-07-27 / GlobalBio & Investment
Atthishigh-impactsession,globalexpertsfromDelosCapital,A*STAR,KuderConsulting,andICONBiotechunpackedkeytrendsshapingthefuture:fromN-of-1personalizedmedicine,tomodularmRNAmanufacturing,andprecision-tar...
